ClinicalTrials.gg
CompletedNCT05504395Updated Aug 9, 2023

A Pharmacokinetic and Safety Study of CSTI-500 in Subjects With Prader-Willi Syndrome

A Phase 1 interventional study of CSTI-500 in Prader-Willi Syndrome, sponsored by ConSynance Therapeutics. Completed at 1 site in United States. Open to participants aged 13 Years to 50 Years. Per ClinicalTrials.gov, last updated 2023-08-09.

Sponsored by ConSynance Therapeutics · Phase 1, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was Feb 2023, 3 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
13 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Prader-Willi Syndrome with a site in United States — 9 open to participants now, 14 under way, 3 of them phase 3. Prader-Willi Syndrome · United States.

Enrollment
43rd of 58
10 · median 23
Started
2022
with 3 others
Phase 1
3 of 69
none open now
Registered
48th of 69
by date
Lead sponsor
2 of 69
ConSynance Therapeutics

Among the 69 studies in Prader-Willi Syndrome with a site in United States, this one is the 43rd largest by enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2022, is one of 3 in phase 1, and was the 48th registered.

Prader-Willi Syndrome

144 studies on the registry are indexed under Prader-Willi Syndrome; 23 are open to participants now.

Browse Prader-Willi Syndrome studies →

Open to participants now

9 of the 69 studies in Prader-Willi Syndrome with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Prader-Willi Syndrome studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 13 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Prader-Willi Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this Phase 1 study is to evaluate the pharmacokinetics (PK) and safety of a single dose of CSTI-500 10 mg in subjects with Prader-Willi syndrome (PWS) between 13 and 50 years of age with a genetically confirmed diagnosis of PWS.

Read the detailed description

This is an open-label, single center, Phase 1 study to evaluate the PK and safety of a 10 mg single oral dose of CSTI-500, a triple monoamine reuptake inhibitor (TRI), in patients with genetically confirmed PWS. The study will consist of a Screening Period of up to 1-3 days prior to the Baseline Visit (Visit 2). In addition to the Screening Visit (Visit 1), eligible subjects will attend five in-clinic site visits for PK blood draws and safety assessments over a 6-day period. At Visit 2 all subjects will receive one single oral dose of CSTI-500 10 mg. Approximately 14 patients aged 13 to 50 years who meet all eligibility criteria will receive one single dose of CSTI-500.

03

Conditions studied

  • Prader-Willi Syndrome

Browse trials for

Keywords

  • PWS
  • Phase 1
  • Single Dose
  • Non randomized
  • PK
  • Safety
04

Who can participate

Ages eligible
13 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects (13-50 years of age at screening) with a documented medical record history of PWS confirmed by genetic testing.
  • Subject must have a reliable caregiver/parent to bring the subject to the site for the visits, remain with the subject during visit times when allowed to be with the subject and respond to any questions during the visits.
  • Female subjects must not be pregnant or lactating and be willing to use double barrier method throughout the study.
  • A normal supine systolic blood pressure must be ≤140 mmHg and ≥100 mmHg; diastolic blood pressure must be ≤80 mmHg and ≥60 mmHg at Screening. Pulse rate must be ≥50 bpm and ≤100 bpm and pulse rate increase on standing must be within acceptable range.
  • All concomitant medications including blood pressure medications and type 2 diabetic medications must be stable for ≥3 months prior to screening (≤10% change). Supplements and vitamins are not considered concomitant medications for eligibility purposes.

Exclusion criteria

Exclusion Criteria:

  • Participation in any clinical study with an drug/device within 3 months prior to screening or during the study.
  • Recent use (within 3 months) of weight loss agents including prescription, herbal medications, and weight loss supplements.
  • Major surgery within 6 months of screening or planned during the study or history of bariatric surgery.
  • Any in the 2 years prior to screening (excluding basal cell carcinoma or squamous cell carcinoma of the skin or cervical carcinoma in situ that have been successfully treated).
  • Current liver, pulmonary, cardiac, or GI disease that would be expected to adversely affect study participation. Stable disease, e.g., asthma or controlled hypertension is not excluded. Liver disease or liver injury as indicated by abnormal liver function tests, , AST, alkaline phosphatase, or serum (≥3X for any of these tests).
  • Unexplained history or presence of combination of unexplained symptoms e.g., dizziness, syncope, fatigue, palpitations/tachycardia, headaches, or exercise intolerance.
  • Heart failure classified per the (NYHA) level II or greater.
  • Myocardial infarction, stroke, or confirmed within the last 5 years.
  • Uncontrolled Type 2 diabetes as defined by ≥ 9% at Screening.
  • Insulin-dependent Type 1 diabetes.
  • Subjects with a history of any suicidal behavior.
  • Inability to swallow the oral capsule whole with water.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    CSTI-500 10mg

    All eligible subjects will be administered a single oral dose of CSTI-500 10 mg at Visit 2

    Drug: CSTI-500

Interventions

  • DrugCSTI-500

    Single 10 mg capsule

    Also known as: AMR-001181

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Maximum observed plasma concentration following drug administration determined directly from the concentration-time profile.

    Time frame: Pre-dose to 1, 2, 4, 8, 12, 24, 48, 72, and 144 hours post-dose

  2. AUC0-72

    Area under the plasma-drug concentration-time curve from pre-dose (time 0) to 72 hours after drug administration

    Time frame: Pre-dose to 1, 2, 4, 8, 12, 24, 48, and 72 hours post-dose

  3. AUC0-inf

    Area under the plasma-drug concentration-time curve from pre-dose (time 0) extrapolated to infinite time

    Time frame: Pre-dose to 1, 2, 4, 8, 12, 24, 48, 72, and 144 hours post-dose

  4. CSTI-500 plasma concentration

    Time frame: 1 hour post-dose

  5. CSTI-500 plasma concentration

    Time frame: 2 hour post-dose

  6. CSTI-500 plasma concentration

    Time frame: 4 hour post-dose

  7. CSTI-500 plasma concentration

    Time frame: 8 hour post-dose

  8. CSTI-500 plasma concentration

    Time frame: 12 hour post-dose

  9. CSTI-500 plasma concentration

    Time frame: 24 hour post-dose

  10. CSTI-500 plasma concentration

    Time frame: 48 hour post-dose

  11. CSTI-500 plasma concentration

    Time frame: 72 hour post-dose

  12. CSTI-500 plasma concentration

    Time frame: 144 hour post-dose

Secondary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    Number of participants with TEAEs, defined as an adverse event (AE) that is new or worsened in severity after the dose of study drug. AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and will be summarized by system organ class, preferred term, and treatment.

    Time frame: From pre-dose to 15 days post-dose

  2. Incidence of clinically significant findings in physical examinations

    Time frame: Screening to 12, 24, 48, 72, and 144 hours post-dose

  3. Incidence of clinically significant findings in vital signs

    Participants will be assessed for any clinically significant changes in vital parameters (blood pressure, heart rate in supine and standing position, respiratory rate, and body temperature). This also includes evaluation of postural orthostatic tachycardic syndrome.

    Time frame: Screening and pre-dose to 1, 2, 4, 8, 12, 24, 48, 72, and 144 hours post-dose

  4. Incidence of clinically significant findings in laboratory values

    Laboratory evaluations include hematology, thyroid function, and chemistry blood and urine laboratory tests.

    Time frame: Screening to 24, 48, 72, and 144 hours post-dose

  5. Incidence of clinically significant findings in 12-lead electrocardiograms (ECGs)

    Time frame: Screening and pre-dose to 2, 4, 8, 12, 24, 48, 72, and 144 hours post-dose

  6. Comparison of CSTI-500 Cmax values obtained from venous blood draws with values obtained from finger prick samples in PWS subjects

    Time frame: Pre-dose to 1, 2, 4, 8, 12, 24, 48, 72, and 144 hours post-dose

  7. Comparison of CSTI-500 AUC0-72 values obtained from venous blood draws with values obtained from finger prick samples in PWS subjects

    Time frame: Pre-dose to 1, 2, 4, 8, 12, 24, 48, and 72 hours post-dose

  8. Comparison of CSTI-500 AUC0-inf values obtained from venous blood draws with values obtained from finger prick samples in PWS subjects

    Time frame: Pre-dose to 1, 2, 4, 8, 12, 24, 48, 72, and 144 hours post-dose

07

Study locations

1 site
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Feb 2023, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2022
First posted
Aug 17, 2022
StartActual
Nov 14, 2022
Primary completionActual
Feb 21, 2023
CompletionActual
Feb 21, 2023
Last update
Aug 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05504395
Lead sponsor
ConSynance Therapeutics
Responsible party
Sponsor
First posted
Aug 17, 2022
Start date
Nov 14, 2022
Primary completion
Feb 21, 2023
Completion
Feb 21, 2023
Last update
Aug 9, 2023

Study contacts

Italo Biaggioni, MD
principal investigator · Vanderbilt Autonomic Dysfunction Center, Vanderbilt University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion